eligibility_summary
Adults ≥18 with relapsed/refractory multiple myeloma after ≥3 prior lines (PI, IMiD, CD38, prior BCMA ok), measurable disease, ECOG ≤2, ≥3‑mo life expectancy, and adequate marrow/renal/hepatic/cardiac function. Exclude CNS MM, plasma cell leukemia, WM/POEMS/active amyloidosis, major cardiac disease/QTc>470, recent/active other cancers or infections (HIV, active HBV/HCV), unresolved toxicities, recent SCT/chemo/radiation/immunosuppression, pregnancy. Contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: AMG 701, a half-life–extended bispecific T‑cell engager (BiTE, antibody biologic) administered subcutaneously (± IV). Mechanism: Simultaneously binds BCMA on malignant plasma cells and CD3 on T cells to form an immune synapse, redirecting and activating cytotoxic T cells to lyse BCMA+ myeloma cells, induces T‑cell activation/proliferation and cytokine release leading to tumor cell apoptosis. Trial: Phase 1b, open-label, dose escalation/expansion to determine RP2D and assess safety/PK/PD in RRMM. Targets/cells/pathways: BCMA-expressing plasma cells (multiple myeloma), CD3+ T cells, T‑cell effector and cytokine-release pathways. Status: Withdrawn for business reasons (not safety).